Login / Signup

Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).

Sara MobarakMehdi SalasiAhmad HormatiJavad KhodadadiMasood ZiaeeFarshid AbediAzadeh EbrahimzadehZohreh AzarkarFariborz Mansour-GhanaeiFarahnaz JoukarSara YeganehTofigh Yaghubi KaluraziMohammadreza NaghipourZeinab MehrabiAmir Reza BahadoriShoeleh YaghoubiRohollah MoslemiHamideh Abbaspour KasgariHafez FakheriMinoo MoghimiAmir Mohammad ShabaniZahra NekoukarFarhang BabamahmoodiAli Reza Davoudi BadabiLotfollah DavoodiMehdi HassaniazadElham BarahimiAbdolali TousiAnahita SadeghiHadiseh HosamirudsariAli Ali AsgariMohammad AbdollahiAmir AnushiravaniMinoosh ShabaniShervin ShokouhiNasim KhajaviradMohammadreza SalehiSeyed Ali Dehghan ManshadiHashem MousaviFarnaz ZolfaghariElmira AzimiAida ZeinaliElham AkbarpourDorsa MeratGholamali EslamiSajedeh MousaviaslSara SayarEsmat RadmaneshMona EbrahimzadehZahra ArizaviSaeed JelvayShokrollah SalmanzadehHani EsmaeilianMorteza MobarakJalal KarimiZahra PoormontaseriNasrollah Hasooni BahriniAtefeh BonyadiFatemeh DehghaniHadi MirzaeiMasoome Noori JangiHossein PourmasoomiLili Rezaie KeikhaieMahdi AfshariAlireza Nateghi BaygiHelia Nateghi BaygiJacob LeviKaitlyn McCannHannah WentzelBryony SimmonsAndrew HillShahin Merat
Published in: The Journal of antimicrobial chemotherapy (2021)
We observed no significant effect of sofosbuvir/daclatasvir versus placebo on hospital discharge or survival in hospitalized COVID-19 patients.
Keyphrases
  • hepatitis c virus
  • double blind
  • clinical trial
  • sars cov
  • placebo controlled
  • phase iii
  • hepatitis c virus infection
  • phase ii
  • study protocol
  • free survival